DiYaLab ZJG Biotech Co., Ltd

DiYaLab ZJG Biotech Co., Ltd established in 2016, focuses on developing laboratory testing products for Autoimmune and Neurological diseases. With two R&D centers in Shanghai and Zhangjiagang, the company occupies a total of approximately 4,000 square meters for R&D, production, and office spaces, and has obtained ISO 13485 international quality system certification.

The company has been granted 50+ national patents (including 9 invention patents) and is recognized as a high-tech enterprise. 86 of its products have been registered and approved by the National Medical Products Administration (NMPA) for market launch, while 84 products have obtained EU CE certification and are sold globally.

As a developer and manufacturer of laboratory testing products for autoimmune and neurological diseases, the company’s team continues to tackle cutting-edge technologies related to the expression and purification of ion channel-type large transmembrane proteins, addressing challenges posed by foreign monopolies in critical areas. Its independently developed "click chemistry" phospholipid complex antigen synthesis technology based on β2-glycoprotein I has filled a technological gap and successfully received national invention patent authorization. The highly sensitive single-molecule neurological disease detection system currently under development is set to break through sensitivity limitations imposed by the blood-brain barrier, enabling single-molecule detection of multiple biomarkers in blood samples. This system will be widely applicable for early diagnosis and efficacy monitoring of neurological autoimmune diseases, cerebrovascular diseases, and neurodegenerative disorders.